AvenCell Therapeutics Doses First Patient in Phase I Trial of Dual-Targeting CAR-T AVC-203

AvenCell Therapeutics has dosed the first patient in its Phase I QUADvance study evaluating AVC-203, a novel CRISPR-engineered allogeneic CAR-T therapy designed to target CD19 and CD20 receptors in relapsed or refractory B-cell malignancies, announced in a press release.

AVC-203 is the first CRISPR-engineered allogeneic dual-targeting CD19/CD20 switchable CAR-T therapy to enter clinical testing. The therapy uses a dimerized receptor construct combining dual-targeting with AvenCell’s proprietary RevCAR switchable receptor, allowing potential expansion to other targets through bi- or tri-specific bridging proteins.

The QUADvance study (AVC-203-01; NCT07284433) follows regulatory clearance from both the FDA and EMA in late 2025, enabling trial initiation at multiple sites in the US and Europe. The program is supported by a grant of up to $40 million from the Japan Agency for Medical Research and Development (AMED) to advance clinical development in Japan and the Asia-Pacific region.